Physician profile
Robert Shurtleff
NPI 1992182869
$4,861.56
in general payments reported to CMS, 2019-2025
38 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.70 · 2022: $531 · 2023: $1,015 · 2024: $1,729 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.23 | 2021-2025 | Qulipta, Ubrelvy, Viberzi |
| Glaxosmithkline, LLC. | $580.90 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $529.42 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $325.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.66 | 2023-2025 | Jardiance |
| Grifols USA, LLC | $270.93 | 2024-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $259.43 | 2022-2025 | Mounjaro, Jardiance |
| Dexcom, INC. | $234.81 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $199.99 | 2022-2024 | |
| Pfizer INC. | $123.87 | 2023-2025 | |
| Novo Nordisk INC | $103.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $96.67 | 2024-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $80.70 | 2023-2024 | |
| Amgen INC. | $78.29 | 2021-2024 | Prolia, Evenity |
| Corcept Therapeutics | $69.03 | 2024 | Korlym |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shurtleff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.